Equities analysts forecast that Viveve Medical, Inc. (NASDAQ:VIVE) will announce sales of $3.63 million for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Viveve Medical’s earnings, with estimates ranging from $3.58 million to $3.71 million. Viveve Medical posted sales of $1.85 million during the same quarter last year, which would suggest a positive year over year growth rate of 96.2%. The firm is scheduled to announce its next quarterly earnings report on Thursday, November 9th.

On average, analysts expect that Viveve Medical will report full-year sales of $3.63 million for the current fiscal year, with estimates ranging from $14.78 million to $16.10 million. For the next financial year, analysts anticipate that the business will report sales of $24.90 million per share, with estimates ranging from $24.50 million to $25.16 million. Zacks’ sales averages are a mean average based on a survey of research analysts that that provide coverage for Viveve Medical.

Viveve Medical (NASDAQ:VIVE) last released its earnings results on Thursday, August 10th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.21. The firm had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $3.24 million. Viveve Medical had a negative return on equity of 244.96% and a negative net margin of 266.93%. The business’s revenue was up 97.4% on a year-over-year basis. During the same period last year, the business earned ($0.66) earnings per share.

VIVE has been the subject of a number of research reports. Raymond James Financial, Inc. initiated coverage on Viveve Medical in a research note on Thursday, May 25th. They set an “outperform” rating and a $10.00 target price for the company. ValuEngine raised Viveve Medical from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Maxim Group reissued a “buy” rating and set a $11.00 target price on shares of Viveve Medical in a research note on Friday, August 11th. Cowen and Company reissued a “buy” rating and set a $11.00 target price on shares of Viveve Medical in a research note on Thursday, August 17th. Finally, B. Riley reissued a “buy” rating and set a $10.00 target price on shares of Viveve Medical in a research note on Wednesday, May 17th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $12.80.

Viveve Medical (NASDAQ:VIVE) opened at 5.43 on Friday. The stock has a 50 day moving average of $6.07 and a 200 day moving average of $6.52. Viveve Medical has a 52-week low of $3.75 and a 52-week high of $11.16. The stock’s market capitalization is $105.37 million.

In other Viveve Medical news, CFO Scott Durbin bought 5,000 shares of the stock in a transaction that occurred on Wednesday, August 23rd. The stock was acquired at an average cost of $5.25 per share, with a total value of $26,250.00. Following the purchase, the chief financial officer now owns 11,568 shares in the company, valued at $60,732. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 35.10% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. California State Teachers Retirement System acquired a new position in Viveve Medical during the 2nd quarter worth approximately $190,000. State Street Corp acquired a new position in Viveve Medical during the 2nd quarter worth approximately $1,282,000. Manatuck Hill Partners LLC boosted its position in Viveve Medical by 128.6% during the 2nd quarter. Manatuck Hill Partners LLC now owns 400,000 shares of the company’s stock worth $2,872,000 after acquiring an additional 225,000 shares during the last quarter. HighTower Advisors LLC boosted its position in Viveve Medical by 33.2% during the 2nd quarter. HighTower Advisors LLC now owns 1,723,751 shares of the company’s stock worth $12,379,000 after acquiring an additional 430,033 shares during the last quarter. Finally, Numeric Investors LLC acquired a new position in Viveve Medical during the 2nd quarter worth approximately $330,000. 65.80% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Viveve Medical, Inc. (VIVE) Expected to Announce Quarterly Sales of $3.63 Million” was posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/08/viveve-medical-inc-vive-expected-to-announce-quarterly-sales-of-3-63-million.html.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Get a free copy of the Zacks research report on Viveve Medical (VIVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.